Select a Community
Are you sure you want to trigger topic in your Anconeus AI algorithm?
You are done for today with this topic.
Would you like to start learning session with this topic items scheduled for future?
Zoledronic acid (Reclast) injection once per year
5%
146/2750
Teriparatide (Forteo) injection once daily
9%
244/2750
Alendronate (Fosamax) oral once weekly
4%
108/2750
Teriparatide (Forteo) continuous infusion for 2 weeks
75%
2060/2750
Alendronate (Fosamax) oral once daily
7%
180/2750
Select Answer to see Preferred Response
Teriparatide (Forteo) comprises the first 34 amino acids of the 84 amino acid sequence that make-up parathyroid hormone(PTH) and can reproduce the primary effects of PTH by activating adenyl cyclase. Continuous infusions of Teriparatide result in a persistent elevation of the serum parathyroid hormone concentration, and lead to greater bone resorption than do daily injections. Daily Teriparatide injections cause only transient increases in the serum parathyroid hormone concentration and creates a net anabolic effect on bone. Alendronate is an oral bisphosphonate that decreases bone resorption and can be administered by taking oral dosages of 70mg once weekly or 10mg once daily. Zoledronic acid is also a bisphosphonate that is administered as an annual infusion. The Level 1 study by Neer et al found that daily treatment with parathyroid hormone (1-34) reduced the risk of nonvertebral fractures by 35 percent at the 20-µg dose and by 40 percent at the 40-µg dose and reduced the risk of nonvertebral fragility fractures by 53 and 54 percent, respectively
3.1
(23)
Please Login to add comment